Global Blood Therapeutics (GBT) Receives Media Sentiment Rating of 0.24
News coverage about Global Blood Therapeutics (NASDAQ:GBT) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.8105212313289 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts have commented on GBT shares. ValuEngine upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Oppenheimer Holdings, Inc. started coverage on Global Blood Therapeutics in a research note on Friday, August 4th. They issued an “outperform” rating and a $53.00 target price for the company. Cowen and Company restated an “outperform” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a research note on Monday, August 14th. Finally, Morgan Stanley restated an “overweight” rating on shares of Global Blood Therapeutics in a research note on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $49.73.
Shares of Global Blood Therapeutics (GBT) traded up 6.06% during trading on Friday, hitting $28.00. The stock had a trading volume of 1,684,553 shares. The stock’s 50-day moving average price is $27.76 and its 200 day moving average price is $30.02. Global Blood Therapeutics has a one year low of $13.35 and a one year high of $41.15. The stock’s market cap is $1.22 billion.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same quarter in the prior year, the firm earned ($0.58) EPS. On average, equities analysts forecast that Global Blood Therapeutics will post ($2.45) EPS for the current year.
In other news, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 143,255 shares of the company’s stock, valued at $4,297,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Deval L. Patrick sold 27,053 shares of the stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the sale, the director now directly owns 12,053 shares in the company, valued at $357,853.57. The disclosure for this sale can be found here. Insiders have sold 33,053 shares of company stock worth $983,204 over the last ninety days. Insiders own 5.30% of the company’s stock.
WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/17/global-blood-therapeutics-gbt-receives-media-sentiment-rating-of-0-24.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.